← back to search

Huyen Cao

Public Health Dayton & Montgomery County ·
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, and COVID-19 Clinical Research Studies.
h-index
34
citations
9,701
works
97
NIH funding
primary concept
Medicine
email

Recent publications

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
UCL Discovery (University College London) 2022cited by 192position: middle
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Intensive Care Medicine 2021cited by 124position: middledoi
Compassionate Use of Remdesivir in Children With Severe COVID-19
PEDIATRICS 2021cited by 103position: middledoi
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
New England Journal of Medicine 2020cited by 1,436position: middledoi
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
JAMA 2020cited by 1,274position: middledoi
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
The Lancet 2015cited by 596position: middledoi
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy
JAIDS Journal of Acquired Immune Deficiency Syndromes 2015cited by 140position: middledoi
Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy
The Journal of Infectious Diseases 2015cited by 84position: middledoi
P99 Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate
Sexually Transmitted Infections 2015cited by 5position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Andrew Cheng · Spero Therapeutics (United States)2 papers (2015–2015)Benoît Trottier · McGill University Health Centre2 papers (2015–2015)Michael T. Yin · Columbia University Irving Medical Center2 papers (2015–2015) · 2 papers (2015–2015)Hal Martin · New York Hospital Queens2 papers (2015–2015)Scott McCallister · Gilead Sciences (United States)2 papers (2015–2015)Frank A. Post · King's College Hospital NHS Foundation Trust2 papers (2015–2015)Michael S. Saag · M4 Engineering (United States)2 papers (2015–2015)Marshall W. Fordyce · Brown University2 papers (2015–2015)Shinichi Oka · AIDS United2 papers (2015–2015)Moupali Das · Gilead Sciences (United States)2 papers (2015–2021)Gordon Crofoot · Indiana University – Purdue University Indianapolis2 papers (2015–2015)Christian Callebaut · Gilead Sciences (United States)2 papers (2015–2015)Joseph M. Custodio · Indiana University – Purdue University Indianapolis2 papers (2015–2015)Diana M. Brainard · Gilead Sciences (France)2 papers (2021–2021)Michael S Saag · University of Alabama at Birmingham1 papers (2015–2015)Paul E. Sax · Harvard University1 papers (2015–2015)Mark J. Siedner · Harvard University1 papers (2015–2015) · 1 papers (2021–2021) · 1 papers (2015–2015)